Clinical Study of 18F-Exendin-4 in Insulinoma
NCT07340437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2026-01-15
Summary
The goal of this observational study is to evaluate the diagnostic value of ¹⁸F-Exendin-4 PET/CT imaging in renal insulinoma. Participants will undergo clinical evaluation and ¹⁸F-Exendin-4 PET/CT examination.
Conditions
- Insulinoma
Sponsors & Collaborators
-
Sichuan Provincial People's Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-01
- Primary Completion
- 2025-10-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
GLP-1 Receptor Targeting in Diabetic and Healthy Individuals
NCT01825148 ·Status: COMPLETED
-
Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes
NCT04733508 ·Status: UNKNOWN ·Phase: NA
-
Regulation of Insulin Secretion by the GLP-1 Receptor
NCT02844907 ·Status: TERMINATED ·Phase: PHASE4
-
New Imaging Procedure for the Localisation of Insulinoma
NCT02127541 ·Status: COMPLETED ·Phase: NA
-
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01449019 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
NCT01185119 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
GLP-1 Receptor Expression in CHI
NCT03768518 ·Status: UNKNOWN
-
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832 ·Status: RECRUITING ·Phase: NA
-
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
NCT00747968 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Imaging Pituitary ActiVation by Exendin
NCT03923114 ·Status: COMPLETED ·Phase: NA
-
Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)
NCT06144255 ·Status: COMPLETED ·Phase: PHASE1
-
18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
NCT01916148 ·Status: AVAILABLE
-
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
NCT02639130 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain
NCT02745470 ·Status: COMPLETED ·Phase: NA
-
Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients
NCT01473147 ·Status: COMPLETED ·Phase: NA
-
Glucagon Like Peptide-1 in Remote Ischemic Conditioning
NCT02746757 ·Status: COMPLETED ·Phase: NA
-
Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes
NCT03392441 ·Status: COMPLETED ·Phase: NA
-
Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
NCT02129985 ·Status: UNKNOWN ·Phase: PHASE4
-
Acute Effects of GLP-1 on Renal Hemodynamics
NCT04337268 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin
NCT01310452 ·Status: UNKNOWN ·Phase: NA
-
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
NCT04459338 ·Status: COMPLETED ·Phase: PHASE3
-
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
NCT03669770 ·Status: COMPLETED
-
Raclopride-PET/MRT
NCT03637075 ·Status: COMPLETED ·Phase: NA
-
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI
NCT01562678 ·Status: COMPLETED ·Phase: PHASE4